Clinical Manifestations
TBM is a disease of young children with 40% patients under 2 years of age and 70% under 5 years at the time of presentation. 1 The clinical presentation of TBM is nonspecific, especially in the early stages of disease. Most patients present with a vague ill health lasting 2-8 weeks prior to the development of meningeal irritation. These nonspecific symptoms include malaise, anorexia, fatigue, fever, myalgias and headache. Children with TBM often present with neck stiffness, seizure and abdominal symptoms such as nausea and vomiting. The neurological picture is mostly the result of combined effect of increased intracranial pressure and infarction. 2 A history of contact is identified in approximately 50 to 60‰ of children. A close association with disseminated tuberculosis is seen in pediatric age. Cranial nerve palsies occur in 20-30‰ of patients. The sixth cranial nerve is most commonly affected. Vision loss due to optic nerve involvement may occasionally be a dominant presenting illness. Ophthalmoscopic examination may reveal papilloedema and choroid tubercle. 3, 4 Clinical entry criteria • Symptoms and signs of meningitis including one or more of the following: headache, irritability, vomiting, fever, neck stiffness, convulsions, focal neurological deficits, altered consciousness, or lethargy. Tuberculous meningitis classification Definite tuberculous meningitis • Patients should fulfill criterion A or B: A) Clinical entry criteria plus one or more of the following: acid-fast bacilli seen in the CSF; Mycobacterium tuberculosis cultured from the CSF; or a CSF positive commercial nucleic acid amplification test. B) Acid-fast bacilli seen in the context of histological changes consistent with tuberculosis in the brain or spinal cord with suggestive symptoms or signs and CSF changes, or visible meningitis (on autopsy). Probable tuberculous meningitis • Clinical entry criteria plus a total diagnostic score of 10 or more points (when cerebral imaging is not available) or 12 or more points (when cerebral imaging is available) plus exclusion of alternative diagnoses. At least 2 points should either come from CSF or cerebral imaging criteria. Possible tuberculous meningitis • Clinical entry criteria plus a total diagnostic score of 6-9 points (when cerebral imaging is not available) or 6-11 points (when cerebral imaging is available) plus exclusion of alternative diagnoses. Possible tuberculosis cannot be diagnosed or excluded without doing a lumbar puncture or cerebral imaging. Not tuberculous meningitis • Alternative diagnosis established, without a definitive diagnosis of tuberculous meningitis or other convincing signs of dual disease. 
Investigation:
The diagnosis of TBM can be difficult. Most important is CSF study. In this section we will discuss how the conventional and advanced investigations help in the diagnosis of TBM.
CSF study: Characteristic CSF findings of TBM include the following :(i) lymphocytic-predominant pleiocytosis. Total white cell counts are usually between 100 and 500 cells/ìL. Very early in the disease, lower counts and neutrophil predominance may be present,(ii) elevated protein levels, typically between 100 and 500 mg/dL, (iii) low glucose, usually less than 45mg/dL or CSF: plasma ratio <0.5. 6 Atypical CSF findings have been described, including normal CSF glucose, protein, cell count, or a neutrophil predominance. Neuroimaging: Neuroimaging is very important in diagnosis of TBM. Cranial computerized tompgraphy(CT) and more recently MRI are extremely helpful in diagnosing and managing TBM and its complications. 18 Classic CT triad of TBM consists of basal meningovascular enhancement, obstructive hydrocephalus and cerebral infarction, most commonly of the basal ganglia. One study found that combination of hydrocephalus, basal enhancement and infarction is 100% specific and 41% sensitive for the diagnosis of childhood TBM. although the authors suggested pre-contrast hyperdensity in the basal cisterns as the best predictor of TBM. 19 , 20 Magnetic resonance imaging (MRI) is the imaging test of choice for visualizing abnormalities associated with TBM. It shows diffuse, thick, meningeal enhancement . Contrast enhanced MRI is generally considered as the modality of choice. It is useful for assessment of the location of lesions and their margins, as well as ventriculitis, meningitis and spinal involvement (sensitivity 86%, specificity 90%). The T2-weighted MRI imaging has been shown to be particularly good at demonstrating brainstem pathology; diffusionweighted imaging (DWI) is best at detection of acute cerebral infarcts due to TBM . Tuberculoma is best evaluated in MRI. The appearance of a solid caseous tuberculoma is that of an isointense or mildly hyperintense brain lesion with marked surrounding low density that demonstrates vasogenic oedema. Marked rim enhancement is always present after contrast administration. A hypointense centre indicates liquefaction and abscess formation. 2 Tuberculous abscesses are larger than tuberculomas (often >3 cm in diameter), solitary, thin walled, and often multiloculated. 21 DWI in tuberculous abscesses has shown restricted diffusion with low apparent diffusion coefficient (ADC) values, probably a result of the presence of intact inflammatory cells in the pus. Unfortunately these radiological features are not specific for tuberculoma . The differential diagnosis of solid tuberculoma includes toxoplasmosis and cerebral tumours, while cystic tuberculomas cannot be differentiated from pyogenic brain abscess and neurocysticercosis on usual imaging alone . 2,22 A large lipid, lactate peak has been used to identify tuberculomas by magnetic resonance spectroscopy (MRS). Serial transcranial doppler ultrasonography (TCD) with blood flow velocity and pulsatility index measurements, can be efficiently utilized to prognosticate outcome in tuberculous meningitis related vasculopathy. 23 Air encephalography is the most reliable way of determining the level of CSF obstruction. If in lateral skull x-ray, air in the basal cistern and lateral ventricles indicates communicating hydrocephalus but air only at the level of basal cistern indicates noncommunicating hydrocephalus. 2
Treatment
Antimicrobial therapy: TBM is a medical emergency and treatment should be initiated as soon as the condtion is suspected because delay is associated with death and disability. Therefore empiric treatment should be started as soon as TBM is suspected clinically. 2 The recommended treatment regimen for presumed drug susceptible TBM consists of two months of daily Isoniazid(INH), Rifampicin(RIF), Pyrazinamide (PZA), and either Streptomycin (SM), or Ethambutol (EMB), followed by 10 months of INH and RIF . 24 INH is considered the most critical of the first-line agents due to its excellent CSF penetration and high bactericidal activity. CSF penetration of INH is about 90 to 95 %. 7 While RIF penetrates the CSF less freely (5%-25%). However, the high mortality of TBM due to RIF-resistant strains has confirmed its importance. PZA has excellent penetration into the CSF (95%-100%) and is a key drug in reducing the total treatment time for drug-susceptible TBM. Hence, if PZA cannot be tolerated, the treatment course for TBM should be lengthened to a total of 18 months. 4 INH kills most of the rapidly replicating bacilli in the first 2 weeks of treatment, with some additional help from SM and EMB. Thereafter, RIF and PZA become important because they "sterilize" lesions by killing organisms; RIF kills low or non-replicating organisms and PZA kills those in sites hostile to the penetration and action of the other drugs. 4
The 4 th drug: There are no data from controlled trials to guide choice of the fourth drug. Most authorities recommend either Streptomycin or ethambutol, although neither penetrates the CSF well in the absence of inflammation, and both can produce significant adverse reactions. SM should not be given to those who are pregnant or have renal impairment and resistance is relatively common worldwide. While EMB-induced optic neuropathy is a concern, especially when treating comatose patients, although at the standard dose of 15 -20 mg/kg, the incidence is less than 3%. 25 The British Thoracic Society (BTS), the Infectious Diseases Society of America and the American Thoracic Society (IDSA/ATS) acknowledge the scarcity of evidence from controlled trials regarding the choice of the fourth drug in the intensive phase. The BTS recommend streptomycin or ethambutol while the IDSA/ATS favor ethambutol, 3, 24 So, treatment should best be started with INH, RIF, and PZA. The addition of a fourth drug is left to the choice of the local physicians and their experience, with little evidence to support the use of one over the other. Some researchers advocate ethionamide, particularly in South Africa. Ethionamide penetrates healthy and inflamed meninges, but can cause severe nausea and vomiting. 25 Duration: Evidence concerning the duration of treatment is conflicting. The duration of conventional therapy is 6-9 months, although some investigators still recommend as many as 24 months of therapy. In the national guideline of Bangladesh for treatment of tuberculosis in children, the recommended duration is 12 month . 26 WHO recommendation for duration is 12 months. 27 Recently , in a study it has been shown that short course intensified treatment ( 6 months INH, RIF, PZA, Ethambutol for HIV uninfected and 9 months for HIV infected patients) is safe for drug susceptible cases. 28, 29 Corticosteroids: Adjunctive corticosteroid increases the survival of patients, improve symptom and seizure control and reduce tuberculoma size and peri-lesional oedema. One possible explanation for the survival benefit is that the anti-inflammatory effects of corticosteroids reduce the number of severe adverse events (9.5% versus 16%), particularly hepatitis. Since there are no controlled trials comparing corticosteroid regimens, treatment choice should be based on those found to be effective in published trials. One recommended regimen for severe TBM is intravenous dexamethasone for four weeks (1 week each of 0.4mg/ kg/day, 0.3 mg/kg/day, 0.2mg/kg/day, and 0.1mg/kg/ day followed by four weeks of tapering oral dexamethasone therapy . 30 WHO recommendation is dexamethasone 0.6mg/kg/day intravenous initially and then orally. It is recommended to reduce the dose weekly to stop over 6-8 weeks. 28 Oral prednisolone can also be given as adjunctive therapy at the dose of 2mg/kg/day for six weeks. 26 MDR TBM: TBM resistant to INH and RIF is described as MDR . No controlled trials have been published for the treatment of MDR TBM. Clinicians of patients with MDR-TBM are left to extrapolate from guidelines for the treatment of pulmonary MDR-TB. The World Health Organization recommends for pulmonary MDR-TB the use of a minimum of four agents to which the M. tuberculosis strain has known or suspected susceptibility including use of any first-line oral agents to which the strain remains susceptible, an injectable agent (i.e., an aminoglycoside or capreomycin), a FQN, and then adding other second-line agents as needed for a total of at least four drugs. 27 Role of other drugs: Ischemic brain damage is the most important reason for the permanent neurological sequelae in TBM. Aspirin is used in this cases due to antithrombotic , anti-ischemic and anti-inflammatory properties . However, in adult Aspirin showed significant reduction in mortality at 3 month while in children it showed no significant improvement in mortality and morbidity at 6 months. 31, 32 Another drug is Thalidomide which is an immunomodulatory agent. In two case series of tuberculomas and tubercular abscess and blindness due to optic arachnoiditis showed dramatic clinical and neuroradiological improvement after low dose of thalidomide. However, caution should be taken as it produces serious side effects. 32 Fluoroquinolones could represent highly effective fourth drugs and are an essential component of treatment regimens for multidrug-resistant cases. Vitamin D supplementation may play role in TBM as in few studies it has been seen that there is an association between tuberculous meningitis and low sunshine hours 3 months before disease . It suggests a possible role for low vitamin D in bacterial dissemination. 28 Fluid Management in TBM: Hyponatraemia is common in TBM and has been related to stage of disease, cerebral perfusion pressure and clinical outcome. It may result from syndrome of inappropriate ADH (SIADH) or cerebral salt wasting (CSWS). Patients with SIADH are euvolaemic or hypervolaemic and need fluid restriction while CSWS is associated with hypovolaemia and requires fluid replacement. A positive fluid balance in TBM is important as there is risk of stroke . In addition diuretic treatment of hydrocephalus should be initiated only once the patient's hydration status has normalized. 2 Conclusion: TBM is a devastating disease. Despite undeniable advances in the investigation in recent years, most of the problems that pediatricians and neurologists face have been solved by the uniform definition of TBM. Still some challenges are yet to solve. Most important are consensus regarding the 4 th drug and MDR TBM treatment. Therefore, new studies in children are urgently suggested. In the meantime, when treating a child with suspected TBM, the most aggressive attitude is to be used both for diagnosis and for therapy.
